Proteomic analysis during stem cell differentiation

干细胞分化过程中的蛋白质组学分析

• 批准号: 6337341
• 负责人: Andrzej K Drukier
• 金额: $ 9.95万
• 依托单位: BIOTRACES, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-06-01 至 2001-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6337341
• 关键词: bioimaging /biomedical imaging; biomedical equipment development; cell differentiation; cytokine; differential display technique; hematopoietic stem cells; imaging /visualization /scanning; photomultiplier; protein structure function; proteomics; retinoate; stem cells; tissue /cell culture

DESCRIPTION (Applicant's Description Verbatim): Stem cells are defined as cells with the ability both to self renew and to differentiate. This property of stem cells underpins growth and differentiation during development and sustains homeostasis and repair processes throughout adult life. The identification of novel proteins that drive pluriopotent stem cell growth or factors that direct their differentiation and lineage commitment, are of fundamental significance in the understanding of stem cell biology and its medical applications. Central to the identification and characterization of these proteins is the availability of a super sensitive method for studying the protein expression profile of these cells under a wide range of conditions in a sensitive, quantitative, and efficient fashion. Alas, the prior-art techniques of differential display of proteins arc not sensitive enough and their dynamic detection range is not adequate for studying low abundance proteins. BIOTRACES has developed a proprietary Multi Photon Detection (MPD) technology. Using MPD technology, we are developing an integrated proteomic system including the MPD Imager for differential display of protein that is at least one hundred times more sensitive than other techniques. The purpose of this Phase I proposal is to apply MPD-based proteomics tools to identify and characterize proteins that are differentially modified or expressed during hematopoietic stem cells lineage commitment and differentiation. PROPOSED COMMERCIAL APPLICATION: MPD has successfully been applied to RNA/DNA analysis, immunoassays and proteomics. The MPD-enhanced analysis of proteins, including better immunoassays for cytokines will enable better biomedical diagnostics and new therapeutic modalities. This is a large, multi- billion dollar/yr market. BioTraces may become a dominant player in part of this market with income estimated to be in the range of 100-200 million dollars annually. We are developing MPD enabled ultrasensitive protein-chips, including the P-chip for stem cells. These new techniques permit us to capture a considerable segment of diagnostic proteomics and diagnostic oncology market.

描述（申请人的逐字描述）：干细胞被定义为细胞 具有自我更新和差异化的能力。茎的这个性质 细胞在发育过程中支持生长和分化并维持 整个成年生活的稳态和修复过程。鉴定 驱动多能干细胞生长的新型蛋白质或指导因子 他们的分化和血统承诺具有根本意义 了解干细胞生物学及其医学应用。中央 这些蛋白质的鉴定和表征 研究蛋白质表达的超灵敏方法的可用性 这些细胞在各种条件下的敏感、 定量、高效的时尚。唉，现有技术 蛋白质的差异显示不够灵敏，其动态 检测范围不足以研究低丰度蛋白质。生物痕迹 开发了专有的多光子检测（MPD）技术。使用 MPD 技术，我们正在开发一个集成的蛋白质组系统，包括 MPD 用于蛋白质差异显示至少一百倍的成像仪 比其他技术更敏感。第一阶段提案的目的是 应用基于 MPD 的蛋白质组学工具来识别和表征蛋白质 在造血干细胞过程中进行差异性修饰或表达 血统承诺和分化。 拟议的商业应用： MPD 已成功应用于 RNA/DNA 分析、免疫分析和蛋白质组学。 MPD 增强的蛋白质分析，包括更好的细胞因子免疫测定，将 实现更好的生物医学诊断和新的治疗方式。 这是一个大型的、多 每年十亿美元的市场。 BioTraces 可能会成为该市场部分市场的主导者 年收入估计在100-2亿美元之间。 我们正在开发 MPD 实现了超灵敏蛋白质芯片，包括用于干细胞的 P 芯片。 这些新 技术使我们能够捕获诊断蛋白质组学的相当一部分， 诊断肿瘤学市场。